Alterity Therapeutics to Present at the Bell Potter Healthcare Virtual Conference
MWN-AI** Summary
Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE), a biotechnology firm focused on developing disease-modifying treatments for neurodegenerative diseases, is set to present at the Bell Potter Healthcare Virtual Conference on November 19, 2025. David Stamler, M.D., the Chief Executive Officer, will lead the presentation, aimed at both current and potential shareholders. The event highlights Australia's premier healthcare companies and will take place at 1:30 p.m. AEDT for Australian attendees and 6:30 p.m. Pacific Time, 9:30 p.m. Eastern Time for participants in the United States.
Alterity's primary focus lies in developing therapies for Parkinson’s disease and similar disorders, with its lead asset, ATH434, showing promising results. The compound has demonstrated clinically meaningful efficacy in a randomized, double-blind, placebo-controlled Phase 2 clinical trial specifically targeting Multiple System Atrophy (MSA), a rare and aggressive form of Parkinsonism. Recent open-label Phase 2 data have further supported ATH434's potential in treating advanced MSA. The company employs a robust drug discovery platform, enabling the creation of patentable compounds designed to address the underlying pathologies associated with neurological diseases.
Headquartered in Melbourne, Australia, and San Francisco, California, Alterity Therapeutics is on the forefront of neurodegenerative disease research. Interested stakeholders can access the webcast registration through the Bell Potter website, allowing them to stay informed about the latest developments in the company's drug development pipeline.
This announcement, authorized by CEO David Stamler, also contains forward-looking statements regarding the company's future, emphasizing the risks and uncertainties inherent in drug development and commercialization. For further details, stakeholders are encouraged to visit Alterity’s official website.
MWN-AI** Analysis
Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE), a biotechnology firm focused on neurodegenerative diseases, is preparing to make a significant presentation at the upcoming Bell Potter Healthcare Virtual Conference. The conference, scheduled for November 18-19, 2025, provides an excellent platform for Alterity to showcase its advancements, particularly concerning its lead asset, ATH434, which is in Phase 2 clinical trials targeting Multiple System Atrophy (MSA).
Investors should closely monitor this presentation as it could provide new insights into the efficacy and progress of ATH434, especially following recent positive data from open-label trials. Given the urgency and unmet need in the field of neurodegenerative diseases, particularly Parkinsonian disorders, the outcomes from these trials could be pivotal for Alterity's market position and stock performance.
The company's strategy of focusing on disease-modifying treatments positions it well in a competitive landscape dominated by symptomatic therapies. The uniqueness of Alterity's approach, coupled with its expansive drug discovery platform, opens the door to potential collaboration opportunities and partnerships, which may enhance investor confidence.
However, potential investors should remain cognizant of the inherent risks associated with biotechnology investments, as highlighted in the company’s forward-looking statements. The volatility tied to clinical trial results, regulatory approvals, and funding requirements can lead to significant stock price fluctuations. Therefore, while the excitement surrounding their innovative therapies is palpable, it is essential to conduct thorough due diligence before making investment decisions.
Overall, as Alterity heads into this critical presentation, market participants should keep a close eye on the emerging data from its clinical programs and the strategic commentary from the management team, which may significantly influence the company’s trajectory and investor sentiment going forward.
**MWN-AI Summary and Analysis is based on asking OpenAI to summarize and analyze this news release.
MELBOURNE, Australia and SAN FRANCISCO, Nov. 12, 2025 (GLOBE NEWSWIRE) -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, today announced that David Stamler, M.D., Chief Executive Officer of Alterity, will deliver a corporate update at the Bell Potter Healthcare Conference, a virtual event showcasing Australia’s best healthcare companies.
Presentation details
| AUSTRALIA PARTICIPANTS: | |
| Date: | Wednesday, 19 November 2025 |
| Time: | 1:30 p.m. AEDT (Sydney/Melbourne) |
| UNITED STATES PARTICIPANTS: | |
| Date: | Tuesday, 18 November 2025 |
| Time: | 6:30 p.m. Pacific Time |
| 9:30 p.m. Eastern Time | |
Current and interested shareholders can register for the webcast here: Bell Potter | Healthcare 2025 (EXT)
About Alterity Therapeutics Limited
Alterity Therapeutics is a clinical stage biotechnology company dedicated to creating an alternate future for people living with neurodegenerative diseases. The Company is initially focused on developing disease modifying therapies in Parkinson’s disease and related disorders. Alterity has demonstrated clinically meaningful efficacy for its lead asset, ATH434, in a randomized, double-blind, placebo-controlled Phase 2 clinical trial in participants with Multiple System Atrophy (MSA), a rare and rapidly progressive Parkinsonian disorder. ATH434 recently reported positive data in its open label Phase 2 clinical trial in advanced MSA. In addition, Alterity has a broad drug discovery platform generating patentable chemical compounds to treat the underlying pathology of neurological diseases. The Company is based in Melbourne, Australia, and San Francisco, California, USA. For further information please visit the Company’s website at www.alteritytherapeutics.com .
Authorisation & Additional information
This announcement was authorized by David Stamler, CEO of Alterity Therapeutics Limited.
Contacts:
Investors
Remy Bernarda
Investor Relations Advisory Solutions
ir@alteritytx.com
+1 (415) 203-6386
Media
Casey McDonald
Tiberend Strategic Advisors, Inc.
cmcdonald@tiberend.com
+1 (646) 577-8520
Forward Looking Statements
This press release contains “forward-looking statements” within the meaning of section 27A of the Securities Act of 1933 and section 21E of the Securities Exchange Act of 1934. The Company has tried to identify such forward-looking statements by use of such words as “expects,” “intends,” “hopes,” “anticipates,” “believes,” “could,” “may,” “evidences” and “estimates,” and other similar expressions, but these words are not the exclusive means of identifying such statements.
Important factors that could cause actual results to differ materially from those indicated by such forward-looking statements are described in the sections titled “Risk Factors” in the Company’s filings with the SEC, including its most recent Annual Report on Form 20-F as well as reports on Form 6-K, including, but not limited to the following: statements relating to the Company’s drug development program, including, but not limited to the initiation, progress and outcomes of clinical trials of the Company’s drug development program, including, but not limited to, ATH434, and any other statements that are not historical facts. Such statements involve risks and uncertainties, including, but not limited to, those risks and uncertainties relating to the difficulties or delays in financing, development, testing, regulatory approval, production and marketing of the Company’s drug components, including, but not limited to, ATH434, the ability of the Company to procure additional future sources of financing, unexpected adverse side effects or inadequate therapeutic efficacy of the Company’s drug compounds, including, but not limited to, ATH434, that could slow or prevent products coming to market, the uncertainty of obtaining patent protection for the Company’s intellectual property or trade secrets, the uncertainty of successfully enforcing the Company’s patent rights and the uncertainty of the Company freedom to operate.
Any forward-looking statement made by us in this press release is based only on information currently available to us and speaks only as of the date on which it is made. We undertake no obligation to publicly update any forward-looking statement, whether written or oral, that may be made from time to time, whether as a result of new information, future developments or otherwise.
FAQ**
How does Alterity Therapeutics Limited (ATHE) plan to leverage its clinical stage status to attract investments in Melbourne, Australia, compared to the competitive biotech ecosystem in San Francisco?
What regulatory challenges could Alterity Therapeutics Limited (ATHE) face while conducting its clinical trials in Melbourne, Australia, relative to those in San Francisco, California?
How does Alterity Therapeutics Limited (ATHE) perceive the investor interest in neurodegenerative disease treatments in both Melbourne and San Francisco, especially following recent trial results?
What marketing strategies will Alterity Therapeutics Limited (ATHE) employ to enhance its visibility in both the Australian and U.S. markets, particularly around its upcoming corporate update presentation?
**MWN-AI FAQ is based on asking OpenAI questions about Alterity Therapeutics Limited (NASDAQ: ATHE).
NASDAQ: ATHE
ATHE Trading
0.17% G/L:
$3.57 Last:
4,812 Volume:
$3.58 Open:
